<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to determine whether <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of thymidylate synthase (TS), excision repair cross-complementing -1 (ERCC-1), excision repair cross-complementing-2 (ERCC-2) and <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> dehydrogenase( MTHFD) <z:chebi fb="2" ids="33699">mRNA</z:chebi> in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> could predict a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response in patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treated with mFOLFOX6 therapy as a first-line treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Eighteen patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treated with mFOLFOX6 therapy as a first-line treatment were enrolled in this study </plain></SENT>
<SENT sid="2" pm="."><plain>There were no significant differences between the response rate and these enzymes <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels </plain></SENT>
<SENT sid="3" pm="."><plain>In ERCC-1 and MTHFD <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, the progression-free survival time tended to be longer in patients with low levels than in patients with high levels( ERCC-1: p=0.08, MTHFD: p=0.07) </plain></SENT>
<SENT sid="4" pm="."><plain>The progression-free survival time was significantly longer in patients with both ERCC-1 and MTHFD <z:chebi fb="2" ids="33699">mRNA</z:chebi> were low levels than in patients with other( p=0.03) </plain></SENT>
<SENT sid="5" pm="."><plain>The levels of ERCC-1 and MTHFD were low in patients who could perform a conversion therapy </plain></SENT>
<SENT sid="6" pm="."><plain>There were no significant differences between an overall survival time and these enzymes <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels </plain></SENT>
<SENT sid="7" pm="."><plain>In this study, the ERCC-1 and MTHFD <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression may be useful for the prediction of progression-free survival time in patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treated with mFOLFOX6 therapy </plain></SENT>
</text></document>